Ym bio sciences corppres ash2012 dec 10 12
YM BioSciences Corporate Presentation
YM BioSciences CorpPres ASH2012 Dec 10 12
Results of the PERSIST-1 phase III study of pacritinib (PAC) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera.
